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Errata
In the article ‘‘Expression and function of neurotrophins and their receptors in cultured human keratinocytes’’ by Marconi
et al (JID 121:1515–1521, 2003), Fig 4a was omitted in error. The figure appears below. The publisher regrets the error.
In the article ‘‘Possible role of apoptosis in the pathogenesis of bleomycin-induced scleroderma’’ by Yamamoto and Nishioka
(JID 122:44–50, 2004), Figs 1, 3, 4, and 5 were published in black and white, although they should have appeared in color.
The figures are reprinted below. The editorial office regrets the error.
Figure 1
TUNEL staining of the lesional skin.
Positive signals were faintly detected in
the hair follicles in the PBS-treated skin
(A). TUNEL-positive cells were detectable
on the cellular infiltrates in the dermis at
1 wk after bleomycin treatment (B), and
further increased at 3 wk (C). TUNEL-
positive cells were also prominently
detected on keratinocytes (D). No positive
signals were observed in negative
controls without TdT (E). On the contrary,
TUNEL was negative on the endothelial
cells even in the sclerotic skin, although
positive on perivascular mononuclear
cells (F). Original magnification: (A,B) 
100; (C)  200; (D)  300; (E)  120;
(F)  400. Scale bars: (A,B) 100 mm; (C)
50 mm; (D) 33 mm; (E) 83 mm; (F) 25 mm.
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Figure 3
Expression of Fas and FasL in the
lesional skin by immunohistochemistry
(A–H) and reverse transcription–PCR
(I). Fas was faintly detected on the hair
follicles, sebaceous glands, and epider-
mis in the PBS-treated skin (A). After
exposure with bleomycin (BLM), Fas was
detected on the cellular infiltrates (B) as
well as fibroblasts (C) in the dermis (B; at
2 wk and C; at 3 wk). FasL was negative in
the PBS-treated skin (D). On the contrary,
FasL was detectable on the cellular
infiltrates as early as at 1 wk after
bleomycin treatment (E), and also ex-
pressed on fibroblasts at 4 wk (F).
Negative controls for Fas (G) and FasL
(H) are shown. Original magnification:
(A,D)  200; (B,C,E–H)  400. Scale bars:
(A,D) 50 mm; (B,C,E–H) 25 mm. (I) Expres-
sion of Fas and FasL mRNA in skin
tissues. Total RNA was extracted from
skin samples treated with either PBS for 4
wk (Cont) or bleomycin for 1 to 4 wk, and
analyzed by reverse transcription–PCR
with specific primers. Results shown are
representative of three independent ex-
periments.
Figure 4
Expression and activity of caspase-3.
Immunohistologic expression of caspase-
3 in the lesional skin following PBS or
bleomycin treatment. Immunoreactivity
for caspase-3 is not detected on the
scattered cellular infiltrates in the PBS-
treated skin (A), whereas detected on the
infiltrating mononuclear cells in the bleo-
mycin-treated skin at 3 wk (B,C). (D)
Representative results of reverse tran-
scription–PCR analysis for caspase-1
and caspase-3 mRNA levels in the skin
following either bleomycin (1–4 wk) or
PBS (3 wk) (Cont) treatment. (E) Colori-
metric assay of caspase-3 activity in the
mice skin treated with either bleomycin or
PBS for 3 wk. Original magnification:
(A)  200; (B)  100; (C)  400. Scale
bars: (A) 50 mm; (B) 100 mm; (C) 25 mm.
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Two errors appear in the publication ‘‘Tumor necrosis factor-
alpha and interferon-gamma polymorphisms contribute to
susceptibility to oral lichen planus’’ by Carrozzo et al (JID
122:87–94, 2004). The seventh author’s name should be
Denise Vezza. In addition, errors were introduced in the
footnotes to Table I. The text of footnote a should
be ‘‘p¼0.0022’’. Footnote b should appear only under the
subheading ‘‘TNF-a-308’’, and not under the subheading
‘‘TGF-b1 cdn 10’’. The text of footnote b should be ‘‘p¼
0.0002’’. There is no footnote c. No superscript ‘‘c’’ should
appear under the subheading ‘‘TNF-a-238’’. The corrected
table is available from http://www.blackwellpublishing.com /
products / journals / suppmat / JID / JID23431 / JID23431sm.
htm. Table S1. IL1 cluster, IL=12, IFNg, TGFb, and TNFa
polymorphisms in OLP patients and controls. The publisher
regrets the error.
In the article by Stern and Nijsten, ‘‘Insuring Rapid and
Robust Safety Assessment’’ (JID 122:857–858, 2004), Dr Ni-
jsten’s name is spelled incorrectly. The authors regret the error.
In the article ‘‘Extracellular matrix protein 1 gene
(ECM1) mutations in lipoid proteinosis and genotype–phe-
notype correlation’’ by Hamada et al (JID 120:345–50,
2003), two errors appear which we wish to correct: (1)
Dr Balasubramanian Jeevankumar’s name was inadvert-
ently omitted from the author list. The correct authorship of
this article is Takahiro Hamada, Vesarat Wessagowit, An-
drew P. South, Gabrielle H. S. Ashton, Ien Chan, Noritaka
Oyama, Apatorn Siriwattana, Prachiya Jewhasuchin, Som-
yot Charuwichitratana, Devinder M. Thappa, Balasubra-
manian Jeevankumar, Patsy Lenane, Bernice Krafchik,
Kanokvalai Kulthanan, Hiroshi Shimizu, Tamer I. Kaya,
Figure 5
Effect of neutralizing anti-FasL antibody. (A,B) Histology of the lesional skin (hematoxylin and eosin stain). Mice were treated with bleomycin
(BLM) 1 mg per mL together with intravenous administration of either anti-FasL antibody or control normal hamster IgG. Mice treated with bleomycin
and normal hamster IgG for 4 wk demonstrate definite dermal sclerosis with thickened collagen bundles (A). Mice treated with bleomycin and anti-
FasL neutralizing antibody for 4 wk show reduction of dermal sclerosis (B). Original magnification: 100. Scale bar: 100 mm. (C) Collagen content
in the skin. Collagen content was significantly suppressed in mice treated with intravenous administration of anti-FasL antibody together with local
bleomycin, compared with those treated with control normal hamster IgG and bleomycin. Data represent the mean  SD of six mice (po0.01). (D)
Morphometric analysis of the number of TUNEL-positive cells per high-power field (HPF) in microscopy. The number of TUNEL-positive
mononuclear cells was significantly decreased in the skin of mice treated with anti-FasL neutralizing antibody compared with that in mice treated
with control normal hamster IgG, together with local bleomycin treatment. (E) Electrophoretic analysis. DNA fragmentation was clearly detected in
DNA extracted from the skin treated with bleomycin and normal hamster IgG for 4 wk (lane 1), which diminished in DNA extracted from the skin
treated with bleomycin and anti-FasL antibody (lane 2). Results shown are representative of three independent experiments. (F) Suppression of
caspase-3 activity. Intravenous injections of FasL antibody together with local bleomycin treatment for 4 wk significantly inhibited the caspase-3
activity, compared with mice treated with normal hamster IgG and bleomycin.
ERRATA 805123 : 4 OCTOBER 2004
Mehmet E. Erdal, Mauro Paradisi, Amy S. Paller, Mariko
Seishima, Takashi Hashimoto, and John A. McGrath; (2) the
correct affiliation for both Balasubramanian Jeevankumar
and Devinder M. Thappa is Department of Dermatology
and STD, JIPMER, Pondicherry, India. The authors regret
the error.
In the published abstract entitled ‘‘Intradermal adminis-
tration of a purinergic agonist augments the induction of im-
munity in mice’’ (J Invest Dermatol 122:A130, 2004 (abstr
#780)), the name of Jing Huang, whose work was done at the
Department of Dermatology at the Weill Medical College of
Cornell University, was inadvertently omitted from the author
list. The correct authorship is R. D. Granstein1, W. Ding1,
J. Huang 1, S. Kodali1, A. Holzer1, K. Seiffert1, A. Di Nardo2,
R. L. Gallo2, and J. A. Wagner3. The authors regret the error.
In the publication ‘‘Update on Cicatricial Alopecia, by Ol-
sen et al (J Investig Dermatol Symp Proc 8:18–19, 2003), the
footnotes in Table I do not correspond correctly to the cit-
ations referred to in the previous publication by Olsen et al
(J Am Acad Dermatol 48:103–110, 2003), which was also
incorrectly cited in the text. The correct references for the
previous article as well as the footnotes are provided in the
table that follows. The authors regret the error.
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Table I. Proposed working classiﬁcation of primary cicatricial
alopeciaa
Lymphocytic
Chronic cutaneous lupus erythematosus (Whiting, 2001)
Lichen planopilaris (LPP) (Mehregan et al, 1992)
Classic LPP
Frontal fibrosing alopecia (Kossard et al, 1997)
Graham–Little Syndrome (Whiting, 2001)
Classic pseudopelade (Brocq)b (Prieto, 1954; Braun-Falco et al,
1986)
Central centrifugal cicatricial alopeciac (Sperling et al, 2000)
Alopecia mucinosa
Keratosis follicularis spinulosa decalvans (Rand and Baden, 1983)
Neutrophilic
Folliculitis decalvans (Whiting, 2001)
Dissecting cellulitis/folliculitis (perifolliculitis abscedens et
suffodiens) (Whiting, 2001)
Mixed
Folliculitis (acne) keloidalis (Rand and Baden, 1983)
Folliculitis (acne) necrotica (Whiting, 2001)
Erosive pustular dermatosis (Caputo and Veraldi, 1993)
Non-specificd
aOlsen et al (2003).
bClinically discrete, smooth, flesh-tone or white areas of alopecia with-
out follicular hyperkeratosis or perifollicular inflammation.
cCicatricial alopecia starting in the central scalp and progressing cen-
trifugally. This entity has previously been referred to by other terms (i.e.,
follicular degeneration syndrome, pseudopelade in African-Americans,
central ellipitical pseudopelade in Caucasians) but we are suggesting this
more descriptive term, which embraces all previous entities.
dNon-specific cicatricial alopecia is defined as an idiopathic scarring
alopecia with inconclusive clinical and histopathological findings. This
category may include the end stage of a variety of inflammatory cicatricial
alopecias such as lichen planopilaris and folliculitis decalvans.
Abstract 085 (Nguyen P, Bazzi H, Kljuic, A et al: Identification
of a novel population of pathogenic autoantibodies against
desmoglein 4 in different major variants of pemphigus. J
Invest Dermatol 122:A15, 2004), published as part of the
2004 SID Meeting Abstracts, was withdrawn 2 d prior to the
April 28 meeting.
In the article by Terrinoni et al, ‘‘A novel recessive connexin
31 (GJB3) mutation in a case of erythrokeratodermia
variabilis’’ (J Invest Dermatol 122:837–891, 2004), Giacinto
Bagetta’s name is spelled incorrectly in the author list. The
authors regret the error.
In the article by Schmuth et al, ‘‘Peroxisome proliferator-
activated receptor (PPAR)-beta/delta stimulates differentia-
tion and lipid accumulation in keratinocytes’’ (J Invest
Dermatol 122:971–983, 2004) ‘‘GW501516’’ should read
‘‘GW1514’’ in line 5 of the abstract, line 8 of Results, and
Fig 1e–h. The authors regret the error.
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